- Iclusig, a new drug for the treatment of chronic myeloid leukemia, has received early approval from the FDA.
- Dr. Samuel Metz considers whether America has the world’s best cancer care.
- Researchers found that pairing cholesterol-reducing drugs called statins with cyclin-dependent kinase inhibitors might more effectively treat certain types of melanomas.
- Adjuvant chemotherapy resulted in higher rates of disease-free and overall survival for women with recurrent breast cancer.
Category Archives: In the News
MSKCC in the News: November 22 – December 5
- In a recent project, described in an article published in Nature Biotechnology, researchers from Johns Hopkins and MSKCC reported concrete steps in the use of human stem cells to test how diseased cells respond to drugs.
- Fitch Ratings has assigned an ‘AA’ rating to Memorial Sloan-Kettering Cancer Center’s approximately $400 million revenue bonds, 2012A.
- Researchers from the Catalan Institution for Research and Advanced Studies (ICREA) in Barcelona and MSKCC have found a key pathway that is responsible for metastasis initiation of colorectal tumors to the liver—a frequent metastasis site for this tumor type. The research is published in Cancer Cell.
- Joshua J. Meeks, MD, and colleagues at MSKCC found that if PSA screening were used uniformly—excluding men with PSA levels above 4—only one of 382 TURPs would identify clinically significant PCa, for a total of 390 in the American population in three years, according to an online report in The Journal of Urology.
Blog Buzz: November 25 – November 30
Overscreening for cancer and ebook reader privacy… just two of the stories making a buzz, but plenty to chew on!
Last Friday, Gary Schwitzer at HealthNewsReview.org gathered some of the very active online commentary related to a recent NEJM paper on mammograms and whether or not they are effective at saving lives. Concerns about the potential harm of overscreening keep coming up regarding breast (and prostate) cancers and make a big media splash each time. Schwitzer’s post, which was updated this week to include more pieces in the NY Times, highlights some of the voices and ideas in the discussion and is a great jumping off point for readers interested in diving in to this complex issue.